肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：乳腺癌中Tamoxifen代谢与疗效

2018-06-01 MedSci MedSci原创

乳腺癌Tamoxifen代谢
关注

Tamoxifen的有效代谢产物endoxifen水平根据CYP2D6酶而变化。CLIN CANCER RES近期发表了一篇文章，通过血浆endoxifen水平和Tamoxifen活性评分（TAS）研究Tamoxifen有效性。

Tamoxifen的有效代谢产物endoxifen水平根据CYP2D6酶而变化。CLIN CANCER RES近期发表了一篇文章，通过血浆endoxifen水平和Tamoxifen活性评分（TAS）研究Tamoxifen有效性。

研究纳入2009年2月至2014年5月之间接受一线Tamoxifen 20mg每天治疗的绝经后激素受体阳性乳腺癌患者。主要的研究终点为通过RECIST评价的客观缓解率。次要终点是临床获益，无进展生存和Tamoxifen耐受性。使用logistic回归分析研究3个月后血浆endoxifen水平与客观缓解率。研究终点也与其他Tamoxifen代谢产物和TAS相联系。研究结果表明，297例患者中247例患者可以评估endoxifen水平，其中209例可以对目标区域进行评估。无进展生存的中位随访时间为32.5个月，62%的患者出现进展。客观缓解率和临床获益分别为45%和84%。客观缓解率与endoxifen无关，且endoxifen增加ug/L客观缓解率的OR值为1.008。综合来说，无研究终点与endoxifen水平，Tamoxifen代谢或TAS有关。

文章最后认为，在达到预想摄入情况下，该临床试验结果不支持在绝经后乳腺癌患者接受Tamoxifen治疗时进行治疗性药物endoxifen监测。

原始出处：
Patrick Neven,Lynn Jongen,et al.Tamoxifen Metabolism and Efficacy in Breast Cancer:A Prospective Multicenter Trial.CLIN CANCER RES.May 2018 doi:10.1158/1078-0432.CCR-17-3028

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707308, encodeId=e1ef1e07308a9, content=<a href='/topic/show?id=f4411e1220a' target=_blank style='color:#2F92EE;'>#Tamoxifen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17122, encryptionId=f4411e1220a, topicName=Tamoxifen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a231383798, createdName=yuhaisheng_ibp_32061721, createdTime=Wed Jun 20 06:25:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321129, encodeId=7d4a321129e8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jun 03 11:16:14 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031785, encodeId=ca6a1031e854e, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 01 12:25:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320542, encodeId=c5be320542bf, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jun 01 12:10:16 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-20 yuhaisheng_ibp_32061721

    #Tamoxifen#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1707308, encodeId=e1ef1e07308a9, content=<a href='/topic/show?id=f4411e1220a' target=_blank style='color:#2F92EE;'>#Tamoxifen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17122, encryptionId=f4411e1220a, topicName=Tamoxifen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a231383798, createdName=yuhaisheng_ibp_32061721, createdTime=Wed Jun 20 06:25:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321129, encodeId=7d4a321129e8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jun 03 11:16:14 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031785, encodeId=ca6a1031e854e, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 01 12:25:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320542, encodeId=c5be320542bf, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jun 01 12:10:16 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-03 大爰

    学习了谢谢分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1707308, encodeId=e1ef1e07308a9, content=<a href='/topic/show?id=f4411e1220a' target=_blank style='color:#2F92EE;'>#Tamoxifen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17122, encryptionId=f4411e1220a, topicName=Tamoxifen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a231383798, createdName=yuhaisheng_ibp_32061721, createdTime=Wed Jun 20 06:25:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321129, encodeId=7d4a321129e8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jun 03 11:16:14 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031785, encodeId=ca6a1031e854e, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 01 12:25:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320542, encodeId=c5be320542bf, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jun 01 12:10:16 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-01 内科新手

    谢谢梅斯提供这么好的信息，学到很多

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1707308, encodeId=e1ef1e07308a9, content=<a href='/topic/show?id=f4411e1220a' target=_blank style='color:#2F92EE;'>#Tamoxifen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17122, encryptionId=f4411e1220a, topicName=Tamoxifen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a231383798, createdName=yuhaisheng_ibp_32061721, createdTime=Wed Jun 20 06:25:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321129, encodeId=7d4a321129e8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jun 03 11:16:14 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031785, encodeId=ca6a1031e854e, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 01 12:25:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320542, encodeId=c5be320542bf, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jun 01 12:10:16 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-01 虈亣靌

    优质资源.共同学习

    0

相关资讯

Lancet oncol：瑞博悉尼联合内分泌疗法治疗绝经后的HR阳性的、HER2阴性的晚期乳腺癌患者可获得良好疗效

在MONALEESA-2试验中，ribociclib（瑞博悉尼）联合letrozole（来曲唑），相比单用来曲唑，作为绝经后的激素受体（HR）阳性、HER2阴性、晚期乳腺癌患者的一线疗法，可延长患者的无进展存活期。MONALEESA-7试验，对瑞博悉尼联合内分泌疗法用于绝经后的HR阳性的晚期乳腺癌患者的疗效和安全性进行评估。MONALEESA-7试验，是在30个国家的188个城市开展的3期随机化、

NCCN临床实践指南：乳腺癌筛查和诊断（2018.V2）

2018年5月，美国国家综合癌症网络(NCCN)发布了乳腺癌筛查和诊断指南2018年第2版，指南主要内容涉及： 指南更新摘要 病史和体格检查 一般风险筛查/随访 风险增加筛查/随访 症状，阳性检查结果 乳腺疼痛

Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果

Tucatinib是一种有效的选择性口服HER2酪氨酸激酶抑制剂，有潜能为应用当前治疗方案仍病程进展的患者提供耐受良好的新的治疗方案。现有研究人员在美国开展一非随机化、开放性1b期临床试验，探究tucatinib联合卡培他滨或曲妥珠单抗应用于HER2阳性的乳腺癌患者时的推荐2期试验剂量、安全性、药代动力学和预活性。本研究招募年满18岁的HER2阳性的已应用过曲妥珠单抗、帕托珠单抗和曲妥单抗emta

Radiology：乳腺癌新辅助化疗反应的评估新方法

本研究旨在确定使用新辅助化疗期间的乳腺癌患者的反应程度相对应的动态光学成像特征。

JAMA Oncology：低脂饮食与乳腺癌生存改善有关，10 年内死亡风险降低 22%

5 月 24 日，《JAMA Oncology》发布了一条论文消息，最新的临床随机试验证据指出，平时保持低脂饮食习惯，与乳腺癌死亡风险降低显著相关，乳腺癌患者自诊断后 10 年内全因死亡风险降低 22%。

Nat Commun：抑制休眠肿瘤细胞的自噬或可阻止乳腺癌复发

根据本周《自然-通讯》发表的一项研究Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence，乳腺癌细胞转移至其它器官并保持休眠状态后，通过自噬确保自身可以长期存活。